SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

“Hmmm” is a community meme token on the Solana network, launched on July 22, 2024, through Pumpfun. It’s a derivative of Pepe the Frog but has evolved into its own distinct meme with a unique identity. The token embraces the humor and intrigue of internet culture, playing on the idea of curiosity and speculation. “Hmmm” captures a playful approach to the world of meme tokens, designed to engage a community driven by fun and the whimsical side of crypto. Hmmm, maybe this’ll send.

hmmm

HMMM crypto is trending as community members highlight its association with Phantom Wallet. Conversations mention potential for significant gains and early hype around the token. Some users are pointing to a possible breakout while others urge caution, and many are sharing links related to the token.

Trump For President

TRUMP CRYPTO is trending amid discussions around Donald Trump's political activities and their potential impact on the crypto market, with community members debating the legitimacy and future prospects of Trump-related digital assets. Some traders are weighing the token's potential, while others voice concerns about its performance and broader implications. The conversation extends to Trump's stance on trade, his relationship with other political figures, and the performance of other Trump-related assets.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol ($VIRTUAL) is trending as traders discuss its recent price surge and potential within the expanding play-to-earn and virtual world sectors, with some community members pointing to its bridging of blockchain with gaming. The community is actively discussing its growing traction and new exchange listings, while debating whether it's still early to invest. Some users are also highlighting its AI agent applications.

Clanker is an autonomous agent for deploying tokens. Currently, users may request clanker to deploy an ERC-20 token on Base by tagging it @clanker on Farcaster.

tokenbot

Clanker Crypto ($CLANKER) is trending due to its small supply and recent activity, with community members noting bullish technical patterns. Speculation around a potential Coinbase listing and ongoing maintenance on the platform are also fueling discussions. Community members are watching closely for a breakout.

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

Plasma (XPL) is trending amid discussions about its potential, with some community members pointing to a listing on a Chinese exchange and a Federal Reserve stablecoin conference as possible catalysts. There's also chatter about a partnership with Alchemy Pay to facilitate fiat on-ramps, while others express concerns about recent price drops and potential market manipulation. Overall, the community is weighing both bullish developments and bearish price action.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending as community members discuss its potential role in ongoing memecoin trading, particularly in relation to Broke Coin on Solana, which is holding a community contest.  Some traders are converting stablecoins for memecoins, while others are commenting on USDC's stability relative to other assets. Broader conversations touch on stablecoin regulation and potential applications in traditional finance.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The DIA is trending amid renewed trade tensions between the U.S. and China, sparked by tariff threats and export restrictions. Community discussions revolve around the potential economic impact and whether a meeting between leaders can de-escalate the situation. Some traders are anticipating market volatility and adjusting their positions accordingly, while others remain optimistic about a resolution.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXP Semiconductors is trending amid discussions about its potential for an earnings beat and strong demand in the automotive sector, while some analysts anticipate a Q3 revenue decline. The community is also focused on Edge AI developments and NXP's partnerships, along with recent analyst rating adjustments and price target changes. Additionally, some chatter points to Graphene and its potential impact to the semiconductor industry.

Got that dog in you? - Fueled by a mantra of tokenized self-belief, doginme is representative of the community's collective efforts to embrace and embolden that dog in them. doginme stands for knowing yourself and having that unshakable drive to keep pushing forward. doginme was originally launched in February 2024 when the Farcaster founder was asked if he owned a dog, to which he replied affirmatively: "no but I got that dog in me"

doginme

$DOGINME is trending as community members rally around its 'dog in me' narrative, emphasizing self-belief and resilience. Recent availability on Coinbase in Singapore and Germany, as well as Revolut, has expanded access. Some traders are pointing to technical indicators, suggesting a potential breakout.

SSgA Active Trust - Financial Select Sector SPDR

Financial Select Sector SPDR Fund

XLF is trending as investors monitor potential subprime auto loan issues and commercial real estate struggles within the financial sector, while others point to positive signals like strong bank earnings and potential regulatory support. Community members are actively discussing technical analysis, potential breakouts, and whether the ETF presents a buying opportunity or is poised for a correction. Option activity suggests some are preparing for a downturn, while others remain bullish on the sector's prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs

Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs. 

<ul class="summary-bullets"><li>The Trump administration is preparing a Section 301 investigation to assess whether U.S. trading partners underpay for prescription drugs, a move that could pave the way for new tariffs.</li><li>Earlier this month, the White House confirmed generic drugs would be excluded from potential duties, reversing earlier discussions under the Section 232 national security review.</li><li>The probe expands Trump’s broader effort to pressure pharmaceutical companies and foreign governments to “equalize” drug prices globally.</li></ul>President Donald Trump’s administration reportedly is stepping up pressure on U.S. trading partners over drug costs, preparing a Section 301 investigation under the Trade Act of 1974 to determine whether countries are underpaying for prescription medicines.The move could pave the way for new tariffs and marks a renewed escalation in Trump’s campaign to “equalize” drug prices globally, according to a Financial Times&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/bce66d6e-57f7-40a2-8225-06a8f50ff657">report</a>, citing three people familiar with the matter.Trump has long argued Americans pay disproportionately high prices for the same drugs sold abroad, citing last week that “in London, you’d buy a certain drug for $130 … and in New York, you pay $1,300 for the same thing.”&nbsp;U.S. drug prices average nearly three times higher than in other developed economies, according to the Rand Corporation. Novo Nordisk’s Ozempic, for instance, costs about $936 per month in the U.S., versus $147 in Canada and $83 in France, KFF data show.<h2 class="st-heading-2">Generic Drugs Excluded From Tariff Plans</h2>Earlier this month, the White House<a href="https://stocktwits.com/news-articles/markets/equity/trump-walks-back-generic-drug-tariffs-after-white-house-clash-over-prices-supply-risks/ch67JdhR30E"> said it isn’t planning tariffs on generic drugs</a>, narrowing the scope of its trade actions. Officials had been weighing such duties under Section 232 of the Trade Expansion Act, which permits tariffs on national security grounds.White House spokesman Kush Desai said the administration “is not actively discussing imposing Section 232 tariffs against generic pharmaceuticals.” The Commerce Department also said such tariffs were unlikely, marking a reversal from Trump’s 2023 campaign pledge to restore domestic production of all essential medicines.Advisers, including members of the Domestic Policy Council and health aide Theo Merkel, warned tariffs on generics could raise prices and cause shortages, given that India supplies nearly half of U.S. generic drugs. Commerce officials, however, continue to explore quotas or incentives to rebuild U.S. drug manufacturing capacity.<h2 class="st-heading-2">Broader Pharma Trade Push&nbsp;</h2>The Section 301 move expands Trump’s broader effort to tie drug pricing policy to trade leverage. Earlier this year, he demanded that pharmaceutical companies offer the U.S. their best global price or face penalties.Major firms, including Pfizer, AstraZeneca, Novo Nordisk, and Eli Lilly, have all held pricing talks with the White House. Trump previously reached a deal with the EU to cap drug import tariffs at 15% and is negotiating with the U.K. for lower duties in exchange for higher payments to drugmakers.While Trump last month threatened 100% tariffs on branded drugs to force companies to expand U.S. manufacturing, those measures have yet to materialize. Officials said firms will be given time to invest domestically and demonstrate pricing reforms.Desai said the White House is pursuing a “multi-faceted approach” that could include federal grants or loans, potentially with funding from foreign partners like Japan, to strengthen U.S. drug supply chains and reduce dependence on imports.<h2 class="st-heading-2">Stocktwits Traders See Muted Interest For Healthcare ETFs</h2>On Stocktwits, retail sentiment toward the Health Care Select Sector SPDR Fund (XLV) was ‘bearish’ and toward the iShares Global Healthcare ETF (IXJ) was ‘neutral,’ both amid ‘low’ message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> is up 7%, while&nbsp;<a href="https://stocktwits.com/symbol/IXJ">IXJ</a> has gained 9%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

Trump Steps Up Pressure On Trading Partners Over Drug Costs, Plans Section 301 Review: Report

The probe expands Trump’s broader effort to pressure pharmaceutical companies and foreign governments to “equalize” drug prices globally.

Equity

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

 JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.


Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

Zacks Investment Ideas feature highlights: XLP, KXI, XLU, VPU, VHT and XLV

As AI-fueled markets show bubble risks, defensive ETFs like XLP, XLU, and XLV offer investors stability and downside protection.

 If the AI Bubble Bursts, Here Are Some Defensive ETFs to Consider 

As AI-fueled gains spark bubble warnings, investors are eyeing defensive ETFs in consumer staples, utilities and healthcare for safety. 

The Trump administration said it isn’t planning to impose tariffs on generic drugs, easing months of debate over levies on most U.S.-dispensed medicines.Officials have been weighing the duties under Section 232 of the Trade Expansion Act, which allows tariffs tied to national security concerns. Trump had earlier proposed 100% tariffs on name-brand drugs starting Oct. 1 but excluded generics and later delayed the move for further talks, The Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/trump-generic-prescription-drug-tariffs-3029e024?mod=hp_lead_pos2">reported</a>.“The administration is not actively discussing imposing Section 232 tariffs against generic pharmaceuticals,” said White House spokesman Kush Desai. The Commerce Department, which is leading the investigation, also stated that tariffs on generics aren’t expected.The decision, which could still change, narrows the Commerce Department’s investigation that initially covered both branded and generic drugs. It marks a reversal of Trump’s 2023 campaign pledge to restore U.S. production of all essential medicines.Opponents within the administration, including members of the Domestic Policy Council and healthcare adviser Theo Merkel, reportedly warned that tariffs on generics could raise prices and cause shortages. They argued that low-cost production in countries like India, which is the source of nearly half of U.S. generics, would make tariffs ineffective.Meanwhile, Commerce Department officials have called for tariffs or quotas to stimulate domestic manufacturing and cut dependence on foreign suppliers in the wake of pandemic-era supply chain disruptions. Protectionists have also described foreign reliance on generics as a national security vulnerability and argued that tariffs, combined with government assistance, could make U.S. production profitable.Desai said there was “no daylight or disagreement” between the White House and Commerce Department on the issue.The debate underscores Trump’s challenge in reshoring industries deemed vital to national security. While the administration wants to spur U.S. output of antibiotics and other everyday drugs, U.S. Trade Representative Jamieson Greer recently said officials are still assessing how best to apply “economic tools” to generics, which are mostly tariff-free.The decision could anger GOP protectionists such as Sen. Rick Scott, who urged tariffs on both branded and generic drugs. Meanwhile, officials are reportedly exploring executive actions such as federal grants or loans to boost domestic generic-drug manufacturing, potentially funded by money from foreign partners like Japan under recent tariff agreements.Desai said the administration is pursuing “a nuanced and multi-faceted approach to onshore manufacturing of generic pharmaceuticals” to avoid future dependence like that seen during the Covid era.On Stocktwits, retail sentiment for the Health Care Select Sector SPDR Fund (XLV) was ‘extremely bullish’, while sentiment for the iShares Global Healthcare ETF (IXJ) was ‘bullish’, with both seeing ‘high’ message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> is up 6.4% so far this year, while&nbsp;<a href="https://stocktwits.com/symbol/IXJ">IXJ</a> has gained 8.5%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025.  (Photo by Win McNamee/Getty Images)

Trump Walks Back Plan To Slap Tariffs On Generic Drugs After White House Clash Over Prices, Supply Risks: Report

The administration is now exploring alternative measures, such as federal grants or loans, to encourage the domestic production of critical generic drugs, aiming to reduce reliance on foreign suppliers, including India.

Why Is This the Best Time to Bet on Consumer Staples ETFs?

As the U.S. government shutdown deepens economic uncertainty, investors may turn to consumer staples ETFs like XLP, FTXG and PBJ for stability.  

US Government Shutdown Puts These ETFs in Focus

The U.S. government shut down on Oct. 1, 2025, as last-minute talks failed. ETFs like TLT, XLV and PSCC hog attention. 

A White House official reportedly said on Friday that countries with existing trade agreements with the U.S. would be exempt from the recently announced pharmaceutical tariffs.&nbsp;According to a Reuters report&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/news/reuters.com,2025:newsml_S0N3U402V:0-latest-drug-tariffs-don-t-apply-to-nations-with-trade-deals-white-house-says/">cited</a> by TradingView, when asked whether pharmaceutical tariffs would apply to trading partners such as the European Union and Japan, which already have trade deals, the official stated that the Trump administration would honor the 15% cap as part of those pacts. Other nations with U.S. trade deals include Vietnam, the U.K., Indonesia, and the Philippines. Major partners like India, Canada, and Mexico have yet to finalize&nbsp;an agreement.The clarification comes after President Donald Trump on Thursday announced a 100% tariff on imported, branded, and patented pharmaceutical drugs starting October 1. In his Truth Social&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/115267512131958759">post</a> announcing the tariffs, Trump only highlighted that an exception would be made for any company that is “IS BUILDING their Pharmaceutical Manufacturing Plant in America.” He explained that “is building” refers to “‘breaking ground’ and/or ‘under construction’.”In a note to investors on Friday morning, Jefferies analyst Akash Tewari described the new pharmaceutical tariffs as "a win for Pharma" and "a light at the end of the Trump tunnel," noting that several large-cap companies have already announced U.S. manufacturing projects. Tewari suggested the tariffs and the MFN pilot program may serve as a symbolic “on paper” win ahead of midterms, with limited material impact on pharmaceutical companies.The 100% tariff is higher than what Trump had indicated in August.&nbsp; He&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">stated</a> that tariffs would be increased over time, allowing companies sufficient time to build factories and relocate production. Trump had said he would start by charging a “small tariff” on pharmaceuticals and raise the rate over a year or more to 150% and even 250%.The&nbsp;<a href="https://stocktwits.com/symbol/IHE">iShares U.S. Pharmaceuticals ETF (IHE)</a> edged 1.3% higher in midday trade. On Stocktwits, retail sentiment around the ETF improved to ‘neutral’ from ‘bearish over the past day. Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> rose 0.86% with retail sentiment trending in ‘bullish’ territory as chatter rose to ‘high’ from ‘normal’ levels.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pce-report-core-inflation-holds-steady-at-2-9-in-august/chDViYeR3eE">PCE Report: Core Inflation Holds Steady At 2.9% In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report

According to a Reuters report cited by TradingView, a White House official stated that the Trump administration will honor the 15% pharmaceutical tariff cap for trade partners such as the EU and Japan, as outlined in existing agreements.

SSgA Active Trust - Health Care Select Sector SPDR

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

XLV
Health Care Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Latest XLV News

XLVHealth Care Select Sector SPDR Fund